title: Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review) [RETIRED]: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
abstract: To perform an evidence-based review of the safety and efficacy of botulinum neurotoxin (BoNT) in the treatment of autonomic and urologic disorders and low back and head pain.
  
  
  
  A literature search was performed including MEDLINE and Current Contents for therapeutic articles relevant to BoNT and the selected indications. Authors reviewed, abstracted, and classified articles based on the quality of the study (Class I-IV). Conclusions and recommendations were developed based on the highest level of evidence and put into current clinical context.
  
  
  
  The highest quality literature available for the respective indications was as follows: axillary hyperhidrosis (two Class I studies); palmar hyperhidrosis (two Class II studies); drooling (four Class II studies); gustatory sweating (five Class III studies); neurogenic detrusor overactivity (two Class I studies); sphincter detrusor dyssynergia in spinal cord injury (two Class II studies); chronic low back pain (one Class II study); episodic migraine (two Class I and two Class II studies); chronic daily headache (four Class II studies); and chronic tension-type headache (two Class I studies).
  
  
  
  Botulinum neurotoxin (BoNT) should be offered as a treatment option for the treatment of axillary hyperhidrosis and detrusor overactivity (Level A), should be considered for palmar hyperhidrosis, drooling, and detrusor sphincter dyssynergia after spinal cord injury (Level B), and may be considered for gustatory sweating and low back pain (Level C). BoNT is probably ineffective in episodic migraine and chronic tension-type headache (Level B). There is presently no consistent or strong evidence to permit drawing conclusions on the efficacy of BoNT in chronic daily headache (mainly transformed migraine) (Level U). While clinicians' practice may suggest stronger recommendations in some of these indications, evidence-based conclusions are limited by the availability of data.
authors.affiliation: Department of Neurology, Klinikum Augsburg, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Naumann
authors.forename: Y
authors.initials: Y
authors.lastname: So
authors.forename: C E
authors.initials: CE
authors.lastname: Argoff
authors.forename: M K
authors.initials: MK
authors.lastname: Childers
authors.forename: D D
authors.initials: DD
authors.lastname: Dykstra
authors.forename: G S
authors.initials: GS
authors.lastname: Gronseth
authors.forename: B
authors.initials: B
authors.lastname: Jabbari
authors.forename: H C
authors.initials: HC
authors.lastname: Kaufmann
authors.forename: B
authors.initials: B
authors.lastname: Schurch
authors.forename: S D
authors.initials: SD
authors.lastname: Silberstein
authors.forename: D M
authors.initials: DM
authors.lastname: Simpson
mesh_terms: D001342:Autonomic Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D001905:Botulinum Toxins / Q000008:administration & dosage*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine; D006801:Humans; D006945:Hyperhidrosis / Q000188:drug therapy; D017116:Low Back Pain / Q000188:drug therapy; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage*; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy
chemical_list: D009466:Neuromuscular Blocking Agents; D001905:Botulinum Toxins